Pregnancy induces cardiovascular adaptations in response to increased volume overload. Aside from the hemodynamic changes that occur during pregnancy, the maternal heart also undergoes structural changes. However, cardiac modulation in pregnancies complicated by gestational hypertension is incompletely understood. The objectives of the current investigation were to determine the role of the natriuretic peptide (NP) system in pregnancy and to assess alterations in pregnancy-induced cardiac hypertrophy between gestationally hypertensive and normotensive dams. Previously we have shown that mice lacking the expression of atrial NP (ANP; ANP À/À ) exhibit a gestational hypertensive phenotype. In the current study, female ANP +/+ and ANP À/À mice were mated with ANP +/+ males. Changes in cardiac size and weight were evaluated across pregnancy at Gestational Days 15.5 and 17.5 and Postnatal Days 7, 14, and 28. Nonpregnant mice were used as controls. Physical measurement recordings and histological analyses demonstrated peak cardiac hypertrophy occurring at 14 days postpartum in both ANP +/+ and ANP À/À dams with little to no change during pregnancy. Additionally, left ventricular expression of the reninangiotensin system (RAS) and NP system was quantified by realtime quantitative polymerase chain reaction. Up-regulation of Agt and AT 1a genes was observed late in pregnancy, while Nppa and Nppb genes were significantly up-regulated postpartum. Our data suggest that pregnancy-induced cardiac hypertrophy may be influenced by the RAS throughout gestation and by the NP system postpartum. Further investigations are required to gain a complete understanding of the mechanistic aspects of pregnancy-induced cardiac hypertrophy. cardiac remodeling, gestational hypertension, natriuretic peptides, pregnancy, pregnancy-induced cardiac hypertrophy, renin-angiotensin system
INTRODUCTION
In normal pregnancy, the cardiovascular system undergoes significant physiological changes to allow for normal maternal function during pregnancy and to provide adequate oxygenation and nutrient supply to the fetus through uteroplacental circulation [1] [2] [3] . Along with the characteristic hemodynamic changes associated with pregnancy, such as increased cardiac output [4, 5] , increased stroke volume, increased heart rate, and decreased vascular resistance [6] , the maternal heart is also subject to extensive remodeling [3, 7, 8] . This remodeling promotes physiological cardiac hypertrophy (CH), which enhances cardiac contractile function [9] . Although there is a strong body of literature to support the maternal cardiac changes occurring over gestation, there are a limited number of longitudinal investigations that assess the regression of pregnancy-induced cardiac remodeling postpartum.
One vasoactive system implicated in normal pregnancy and in varying forms of CH is the renin-angiotensin system (RAS). It has been postulated that RAS plays a pivotal role throughout gestation in regulating maternal blood pressure (BP) and sodium/water retention [10, 11] . In pregnancy, studies have reported increased plasma levels of angiotensin-I (ANG-I), angiotensin-II (ANG-II), and the proteolytic enzyme renin [10, 12, 13] . Additional associations between RAS alterations and pregnancy complications, such as pre-eclampsia (PE), have also been established. These studies have described a lower level of expression of the RAS components in pre-eclamptic patients compared to uncomplicated pregnancies [12, 13] .
Atrial natriuretic peptide (ANP), a protein hormone of the natriuretic peptide (NP) family, is produced primarily in the atria of the heart [14] and possesses a cardioprotective function. In cases of hemodynamic stress, up-regulation of fetal genes, such as ANP and B-type NP (BNP), in addition to beta-myosin heavy chain and alpha-actin, often precede the presence of CH [15, 16] . In these situations, increased levels of ANP and BNP function to counterbalance increased BP and cardiac stress by stimulating vasodilation and diuretic and natriuretic processes [17] . Much of the focus surrounding cardiac expression of ANP and BNP, however, has been limited to cases of pathology, such as myocardial infarction and essential hypertension, with insufficient evidence of their direct role in pregnancy-induced CH.
Mice with a disruption in the Nppa gene (ANP À/À ), the encoding gene for ANP, lack expression of ANP, are chronically hypertensive and salt sensitive, and exhibit increased left ventricular hypertrophy (LVH) independent of arterial BP [17, 18] . Moreover, ANP À/À dams display a gestational hypertensive phenotype. While ANP À/À pregnant mice experience significant elevations in BP compared to normotensive controls, both ANP þ/þ and ANP À/À dams demonstrate a biphasic increase in systolic and diastolic BP with a nadir at Gestational Day (GD) 9 [19] . With the use of this murine model, we therefore sought to 1) evaluate the onset and regression of CH between normotensive (ANP þ/þ ) and hypertensive (ANP À/À ) dams to better understand the role of ANP in pregnancy-induced CH and 2) assess whether gestational hypertension exhibited by ANP À/À dams alters pregnancy-related cardiac remodeling. Being that both the RAS and the NP system exhibit unique functions in the development of either physiological or pathological CH, we were interested in characterizing the expression of these vasoactive systems over gestation and postpartum to elucidate their implication in pregnancy-induced CH.
MATERIALS AND METHODS

Animals and Husbandry
All experimental protocols pertaining to the use of mice in this study received approval by the University Animal Care Committee of Queen's University. Animal ethics were also in accordance with the guidelines of the Canadian Council of Animal Care. Mice were bred in-house up to four animals per cage (maintained at room temperature: 21 6 18C) and cared for in the Queen's University Animal Care Facilities. Normal chow and tap water were provided ad libitum and mice maintained on a 12L:12D cycle. Female ANP þ/þ (C57BJ/6) and ANP À/À (C57BJ/6 3 SV129 background) mice were mated between the ages of 10 and 14 wk with ANP þ/þ males. Detection of a copulation plug was deemed GD 0.5. To evaluate the onset and regression of pregnancy-induced CH between normotensive and hypertensive dams, female mice were euthanized prior to giving birth at 15.5GD and 17.5GD and following birth at 7 days postpartum (PP), 14PP, and 28PP. Nonpregnant female mice were used as a control (referred to as NPC). Live fetuses, embryo resorption, and litter size at birth were recorded. The litters of those pregnancies followed to 28PP were weaned at 21 days of age.
Tissue Collection
On euthanasia, all dams were anesthetized via an i.p. injection of Euthanyl (100 mg kg À1 body weight). Maternal ANP þ/þ and ANP À/À hearts were excised, and their wet weight was recorded. The individual chambers of each heart were further isolated, and wet weights were recorded and snap frozen for molecular analysis (n ¼ 6; all time points each genotype). The length of the left femur was measured using digital calipers following soft tissue digestion overnight at 608C in 0.2 M NaOH and used to normalize all cardiac weights. Additionally, four placentas from the right uterine horn of each dam (15.5GD and 17.5GD) were isolated and weighed to obtain mean placental weight.
Cardiac Histology
To assess pregnancy-induced changes in cardiac morphology, a subset (n ¼ 4) of ANP þ/þ and ANP À/À mice were assessed by histology. NPC and 14PP mice were anesthetized and transcardially perfused through the left ventricle (LV) with buffer containing 140 mM NaCl, 10 mM KCl, and 5 mM EDTA followed by 4% paraformaldehyde in PBS at a perfusion pressure of 80 mm Hg. Hearts were paraffin embedded and cross-sectioned through the ventricles at a thickness of 5 lm. Slides were cleared of paraffin, rehydrated through a series of toluene and ethanol (EtOH) gradients, and stained with Weigert iron hematoxylin (1% in EtOH) and eosin (Fischer Scientific). Masson Trichrome (HT15-IKT kit; Sigma-Aldrich). stain was used to assess collagen content.
To quantify changes in LV size, the area of the LV wall (cardiac muscle) was calculated by subtracting the lumen area from the area of the entire LV cross section, both of which were measured using ImageJ software. Additionally, lumen area was used to predict LV lumen diameter by assuming the area of a perfect circle using the following equation: Diameter ¼ 2 3 ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi ðarea 4 pÞ p . To determine whether changes in cardiac size are due to cellular hypertrophy or hyperplasia, cardiomyocyte area was measured in the free wall of the LV using ImageJ. Cells present in cross section (short axis) with a visible nucleus and clear cytoplasmic membrane were used for analysis. Cardiomyocyte area is reported as an average taken from a total of 50 cells from each histological section.
RNA Isolation and Real-Time Quantitative PCR
Total RNA was isolated from frozen LV samples and reverse transcribed as previously described [20] . Gene mRNA expression was measured using a LightCycler 480 II system (Roche Scientific), and the standard-curve method for each gene was employed using hypoxanthine-guanine phosphoribosyltransferase (Hprt) as the reference gene. Cycling parameters consisted of denaturation at 958C for 5 min, followed by touchdown annealing temperatures at 68-628C (decreasing step size of 0.58C per cycle) for 15 sec and 728C for 15 sec to ensure precise hybridization. Melt curve analyses were performed to ensure quality and specificity of real-time quantitative PCR (qPCR) products. All primer sets were designed using Primer Design 2.0 software (Scientific & Educational Software) from published mRNA sequences from the NIH GenBank (www.ncbi.nlm.nih.gov/Genbank; National Center for Biotechnical Information). Primer sequences and efficiencies can be found in Table 1 . All primer standard curve efficiencies were between 1.8 and 2.0.
Data and Statistical Analysis
All statistical analyses were performed using Prism 6.0 Software (GraphPad Software Inc.). Comparisons between groups were performed by either oneway or two-way analysis of variance (ANOVA) with Sidak post hoc test where necessary. Multiple comparison tests were conducted to assess within-genotype comparisons across time in addition to across-genotype within each time point. Variable interactions were not observed for all two-way ANOVA analyses. In all cases, P 0.05 were deemed statistically significant. The Grubb test was used to ensure no major outliers were present. Data are presented as mean 6 standard deviation (SD) or mean 6 standard error of the mean (SEM) where appropriate.
RESULTS
Pregnancy-Induced CH in ANP
þ/þ and ANP
À/À Dams Peaks in Early Postpartum Period
Comparison within genotype demonstrated significant increases in whole heart and individual cardiac chamber wet weights at 14PP in both ANP þ/þ and ANP À/À dams (Figs. 1 and 2). Hypertensive, ANP À/À mice exhibited larger hearts at baseline (NPC), which remained consistently higher at all gestational and postpartum time points compared to their counterpart (Fig. 1A) . This observation was consistent in all four cardiac chambers (Fig. 1, B-E) . Assessment of NPC and 14PP maternal hearts by light microscopy further confirmed this observation. The degree of change in cardiac size is shown in the ventricular cross-section images depicted in Figure 2A . Further histological analysis revealed significant increases in LV wall area and LV lumen diameter from NPC to 14PP in ANP þ/þ dams (P ¼ 0.02 and P ¼ 0.008, respectively). Similar trends were observed in ANP À/À dams (P ¼ 0.09) (Fig. 2, B and C) . At 14PP, cardiomyocyte area was greater than NPCs, demonstrating that increases in cardiac size are attributed to cellular hypertrophy and not hyperplasia. These differences were significant in ANP þ/þ dams (P ¼ 0.02) and approached significance in ANP À/À dams (P ¼ 0.07). Moreover, differences in collagen deposition or cardiac fibrosis were not observed when tissue samples were examined after Masson trichrome stain (data not presented).
Lack of Maternal ANP Does Not Influence Pregnancy Success or Placental Weight
Following euthanasia, viable embryo and embryo resorption numbers were recorded for both 15.5GD and 17.5GD time points. Litter size was also recorded at birth at all postpartum time points (7PP, 14PP, and 28PP). Significance was not achieved in either measure (Table 2) . Additionally, significant differences in mean placental weight were not observed across ANP þ/ þ and ANP À/À dams (data not presented). These results are consistent with our previous investigation [19] .
VENTURA ET AL.
Gestational Elevations in Cardiac RAS Expression Are Attenuated Immediately Postpartum
Observed LV expression of components of the RAS in ANP þ/þ and ANP À/À dams is presented in Figure 3 . Gene expression of Agt (Fig. 3A) and the rodent isoform of the ANG-II receptor 1 (At 1a ) (Fig. 3B) was significantly increased at 17.5GD and not at 15.5GD (P ¼ 0.1). The expression of these genes reverted to baseline NPC levels in both ANP þ/þ and ANP À/À dams by 7PP. LV expression of Agt and At 1a did not differ between genotypes. Angiotensin converting enzyme-1 (Ace1) displayed peak levels in gene expression at 7PP and 14PP in ANP þ/þ and ANP À/À dams (Fig. 3C) . Across time points, ANP À/À mice displayed slightly lower levels of Ace1 expression compared to their counterpart. This difference in expression reached significance only at 14PP (P ¼ 0.02).
Postpartum CH Is Associated with Elevations in Nppa and Nppb Expression
Expression of the genes encoding for NPs, ANP, and BNP (Nppa and Nppb, respectively) and NP receptor C (NPRC, gene ¼ Npr3) was measured in the LV of ANP þ/þ and ANP À/ À dams by qPCR (Fig. 4) . Gene expression of NP receptor A (NPRA, Npr1) and B (NPRB, Npr2) was also measured; however, detection was not achieved. Moreover, due to the transgenic background of ANP À/À mice, Nppa expression was not detected in the LV of ANP À/À dams. LV expression of Nppa in ANP þ/þ dams demonstrated low levels during gestation equivalent to NPCs with significant elevation in gene expression at 7PP and 14PP that gradually declined at 28PP (Fig. 4A) . Similar expression was observed in Nppb across ANP þ/þ and ANP À/À dams with significant elevations in gene expression postpartum (7PP and 14PP) (Fig. 4B) . However, ANP À/À mice displayed a lesser degree of Nppb elevation postpartum compared to ANP þ/þ dams as demonstrated by multiple comparison analysis across genotype. Expression of the NP clearance receptor Npr3 gene exhibited no differences between genotypes with slight increases in gene expression in both groups at 7PP compared to NPCs (Fig. 4C) .
DISCUSSION
CH is an adaptive response of the myocardium to either a pressure-or a volume-overload stimulus [9, 15, 16] . These adaptive responses can cause dramatic structural changes in the heart with respect to cardiac chamber size and wall thickness. In pregnancy, a notable increase in blood volume occurs within the first few weeks of gestation [21] , stimulating a hypertrophic growth response in the heart. Unlike the concentric, irreversible characteristics associated with pathological cardiac remodeling and pressure overload [22] [23] [24] [25] , pregnancy induces CH that is eccentric in nature and reversible [2, 3, 26] . This remodeling is synonymous with that observed during maturation and with respect to exercise due to vascular volume overload accompanying each of these processes [27] [28] [29] . The response of cardiomyocytes to volume overload includes the addition of sarcomeres in series to existing sarcomeres, resulting in increased chamber diameter without increasing wall thickness. Additionally, this type of cardiac remodeling has been shown to enhance contractile function, an essential requirement in pregnancy to allow for the maternal system to successfully adapt to the increased metabolic need of the fetus [1] [2] [3] .
It has been well established that the structure of the maternal heart in uncomplicated pregnancy is significantly altered and that the changes observed during pregnancy regress postpartum. Many investigations have demonstrated an approximate 15-20% increase in ventricular wall thickness and a 40-50% increase in LV wall mass alone by the end of gestation [2, 3, 26, 30] . Additionally, studies involving echocardiography in normal pregnancy have also shown mild dilation in all four cardiac chambers of the heart [16] . The body of literature surrounding pregnancy-induced CH focuses highly on changes during gestation. Currently, knowledge of the mechanisms by which pregnancy-induced cardiac modifications reverse postpartum is limited. This is partly due to the lack of detailed longitudinal studies in both human and animal models.
In our investigation, we have characterized the onset and regression of pregnancy-induced CH in both normal pregnancy and pregnancy complicated by gestational hypertension and lack of maternal ANP monitoring of both ANP þ/þ and ANP À/À dams up to 28PP. At baseline, ANP À/À mice exhibit CH prior to pregnancy, a significant difference in cardiac size that persisted across gestation and postpartum. This characteristic is 
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attributed to the chronic hypertensive nature of the ANP À/À mouse. Pregnancy-induced cardiac changes in normotensive and hypertensive dams displayed peak CH at 14PP, contradicting the current literature that the mouse heart is the largest during pregnancy. Although ANP À/À dams exhibit larger hearts at this time point postpartum, it is important to mention that identical trends in cardiac change were observed in both hypertensive dams and control groups, suggesting that the presence of chronic hypertension and/or lack of ANP expression did not influence pregnancy-related cardiac remodeling in pregnant mice. Other investigations have also reported sustained pregnancy-induced CH postpartum in normal [1, 7, 31] and pre-eclamptic [32] pregnancies. Thus, along with our data set, there is a growing body of evidence to suggest that the critical window of significant maternal cardiac change occurs early postpartum. As a result, mothers, especially those who have experienced pregnancy complications, should be closely monitored during this time.
As previously mentioned, the biological roles of circulating RAS are BP regulation and fluid homeostasis. During pregnancy, an overexpression of the RAS components [12, 13, 33, 34] have been observed with the exception of ACE, which displays decreased expression [13] . Expression of the RAS has been observed in placental spiral arteries and is suggested to be involved in blood volume maintenance and uteroplacental circulation [35] . Furthermore, due to alterations in receptor phenotypes observed over gestation, pregnant women are less sensitive to ANG-II infusion experiments and thus require approximately twice the amount of ANG-II to elicit a similar vasomotor response compared to NPCs [36] [37] [38] . This explains why pregnancy is associated with hypotension while AGT and ANG-II levels remain increased. Moreover, the amount of AGT, a key factor in circulating RAS activity, is highly influenced by estrogens, stimulating increased production of AGT and renin as plasma estradiol levels increase during pregnancy [39] . Our data have further confirmed the increased expression of Agt and At 1a late in pregnancy in both ANP þ/þ and ANP À/À dams. The expression of the components of the RAS was significantly reduced within the first week postpartum, which we speculate may be partly due to inhibition via the postpartum increase in NP system expression. However, the process of delivery and other physiological postpartum alterations are more likely to influence these expressional changes, as ANP À/À dams also demonstrated similar decreases in postpartum RAS expression.
Contrary to normal pregnancy, pregnancy complications such as PE have shown a shift in circulating RAS expression, displaying decreased levels compared to those observed in CARDIAC HYPERTROPHY IN PREGNANCY PEAKS POSTPARTUM uncomplicated pregnancy [12, 13] and increased ANG-II sensitivity [36] . Although ANP À/À dams exhibit gestational hypertension, these mice did not display significant differences in RAS expression compared to ANP þ/þ mice. This could be, in part, due to the transgenic nature of our model. Close examination of the Agt and At 1a data displays slight decreases in expression within the ANP À/À animal; however, these reductions are quite minimal.
It has been well established that the members of the NP family, specifically ANP and BNP, oppose hypertrophic processes in cases of pathological cardiac remodeling. BNP has long been recognized as a biochemical marker used to predict LVH or LV remodeling [40] . In the spontaneously hypertensive rat, ANP and BNP have been shown to display increased levels of expression prior to the development of hypertension in both male and female offspring [41] . Furthermore, the hypertensive and hypertrophic phenotype exhibited by our ANP À/À mouse model [17] is added proof of the importance of these peptides for normal cardiovascular function. Contrary to its characterization in pathological CH, the pattern of ANP and BNP expression in pregnancy has not been extensively studied.
The role of the NP system in pregnancy remains a topic of controversy. A review by Fournier and colleagues in 1991 [42] presented many conflicting and inconsistent results observed across the literature with respect to ANP plasma levels in pregnancy. Similar conclusions regarding the role of BNP in pregnancy have also been made [43] . Some investigations have shown increases in circulating ANP during pregnancy occurring prior to hypervolemia and increased cardiac preload [44] . It is understood that this elevation in ANP permits volume expansion through vasodilation, ensuring adequate blood supply to the fetal-placental unit [44] [45] [46] [47] . This is partially accomplished through the antagonistic effect of ANP on ANG-II-induced vasoconstriction of the uterine artery [48] . Although the aforementioned investigations demonstrate the importance of ANP in pregnancy, there is a lack of knowledge surrounding the expression of the NP system and its function in pregnancyinduced CH.
In our investigation, we have particularly focused on the maternal cardiac expression of the NP system over pregnancy and postpartum. We have observed an up-regulation of Nppa and Nppb gene expression at 7PP and 14PP correlating with peak postpartum CH. These data are suggestive of a protective role for ANP and BNP in counterbalancing the effects of postpartum CH in the heart and a potential influential system involved in the observed initiation of cardiac regression to NPC levels at 28PP. Direct evidence for a cardioprotective function of ANP came from a study by Kato et al. [49] , who showed that ANP promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin (a cytoskeletal focal adhesion component protein) and Akt (or protein kinase B, PKB). These data suggest that both zyxin and Akt participate in a cGMP-dependent signaling cascade leading from ANP receptors to nuclear accumulation of these molecules to induce resistance to cell death. Additionally, genotypic differences in Nppb expression were observed in ANP þ/þ and ANP À/À dams. This may be due to the fact that the hearts of ANP þ/þ mice responded more drastically to pregnancy as shown by their change in LV area and LV diameter (1.5-and 1.2-fold increase, respectively) compared to ANP À/À dams (1.2-and 1.1-fold increase, respectively). It may be possible that because of their chronically hypertensive phenotype, the ANP À/À mouse possesses an unknown mechanism that protects against or limits further cardiac modification, thus requiring less BNP to counterbalance pregnancy-induced changes in the heart. Expression of Nppa and Nppb during pregnancy, however, did not fluctuate from baseline levels. Our results corroborate the current literature, as this has also been previously observed by Eghbali et al. [16] , who assessed ANP expression during pregnancy in comparison to a stimulus of pathological CH. Further mechanistic work is required to elucidate the direct role of the NP system in postpartum CH.
In conclusion, our data set is one of the first to assess the onset and regression of pregnancy-induced CH in normotensive and hypertensive dams using the ANP À/À mouse. We have been able to demonstrate that the maternal heart undergoes the largest change in size within the first 2 wk postpartum following both normal pregnancy and pregnancy complicated by a gestational hypertensive phenotype. Unexpectedly, the lack of maternal ANP and hypertension exhibited by ANP À/À dams did not affect the remodeling of the maternal heart or greatly impact the cardiac gene expression of the RAS and NP system compared to wild-type controls. Furthermore, components of each vasoactive system assessed by qPCR highlighted the importance of the RAS during pregnancy, in particular, late in gestation, and a much larger role for the NP system postpartum. Future work is required to determine a mechanistic understanding of the systems involved in the development of postpartum CH and its implication on maternal cardiac function.
